Turning Point Brands Bets Big on Modern Oral Growth

Turning Point Brands Inc ((TPB)) has held its Q4 earnings call. Read on for the main highlights of the call.

Turning Point Brands delivered an upbeat earnings call, underscored by sharp revenue and EBITDA growth, surging Modern Oral sales, and a cash-rich balance sheet that gives room to invest. Management acknowledged near-term margin pressure from marketing, tariffs, and regulatory costs, but framed these as deliberate, front-loaded bets to secure long-term share in the fast-growing white pouch category.

Consolidated Revenue Surges on Modern Oral Momentum

Consolidated revenue climbed 29% year over year to $121.0 million in Q4 2025, with Modern Oral emerging as the primary engine of growth. The company generated $41.3 million in net revenue from white pouches alone, highlighting a decisive shift in its revenue mix toward next-generation products.

Adjusted EBITDA Grows, but Margin Feels Investment Pressure

Adjusted EBITDA improved 14% to $30.0 million, translating to a 24.8% margin despite heavier spending. Management emphasized that profitability remains solid even as it leans into higher marketing and distribution costs to capture Modern Oral demand, suggesting underlying operating strength.

Modern Oral Becomes Core Growth Engine

Modern Oral white pouch sales exploded, with net sales up 266% year over year and gross sales up 337%, now accounting for 34% of consolidated net sales versus just 12% a year ago. This rapid scale-up confirms strong consumer adoption and positions the segment as the central driver of Turning Point Brands’ future growth story.

Stoker’s Segment Delivers Scale and Stability

The Stoker’s segment posted net sales of $81.0 million, up 70% year over year, and now represents 67% of consolidated net sales. Legacy Stoker’s brands still grew a healthy 9% to $39.7 million, illustrating that traditional products remain an important profit and cash generation pillar alongside newer offerings.

Cash-Rich Balance Sheet Supports Aggressive Investment

Turning Point Brands ended the quarter with $222.8 million in cash and generated $19.2 million of free cash flow in Q4, against modest quarterly CapEx of $3.3 million. This financial flexibility allows the company to fund marketing, regulatory efforts, and manufacturing expansion without straining the balance sheet.

Management Sets Ambitious 2026 Targets for Modern Oral

The company introduced FY2026 guidance for Modern Oral, calling for gross sales of $220–240 million and net sales of $180–190 million, indicating continued triple-digit growth from today’s base. For Q1 2026, management expects adjusted EBITDA of $24–27 million, even as it ramps spending behind white pouch marketing.

Go-to-Market Execution Accelerates Across Channels

Management highlighted strong progress in go-to-market initiatives, with the ALP brand moving from direct-to-consumer into physical retail ahead of schedule and broader rollout slated for Q2. FRE distribution is also expanding across large chains and independents, supported by an aggressive plan to roughly double the sales force.

U.S. Manufacturing Build-Out Aims to Unlock Margins

The build-out of U.S. manufacturing is advancing, with initial production lines at the new factory expected to be qualified in the coming months. Over time, onshore production should ease supply constraints and help lift margins, although the company will still rely on its Indian partner during the ramp phase.

Higher SG&A Reflects Front-Loaded Growth Investments

SG&A rose to $47.7 million in Q4, up $3.1 million sequentially, driven by planned sales and marketing spend behind Modern Oral and higher outbound freight. While this pressures near-term operating leverage, management portrayed the spending as strategic and necessary to build sustainable brand equity and distribution.

Zig-Zag Decline Mirrors Strategic Focus Shift

Zig-Zag revenue fell 13% year over year to $40.0 million and 9% sequentially, a decline management said was anticipated as resources pivot to Modern Oral. The commentary suggested that while Zig-Zag remains part of the portfolio, it is no longer the key growth focus for the company.

Gross Margin Flat as Mix and Tariffs Weigh

Consolidated gross margin held steady at 55.9% year over year despite robust top-line growth, as negative mix and tariffs offset operating gains. The rising share of Modern Oral and a higher tariff rate in the Stoker’s segment created headwinds, tempering the immediate margin benefit of scale.

Lumpy, Front-Loaded Spending Clouds Near-Term Visibility

Management cautioned that sales and marketing investments will be lumpy and front-loaded through 2026, including promotional spending that may show up as contra revenue. This pattern could compress margins and make EBITDA trends beyond Q1 less predictable, even if longer-term returns are attractive.

Domestic Production Ramp Will Be Gradual

While U.S. production lines are moving toward qualification, the company expects a transition period during which it still relies heavily on its Indian manufacturing partner. Margin benefits from domestic production are likely to materialize only later in the year as new inventory flows and efficiency gains filter through results.

Regulatory and Tax Costs Add Structural Overhead

Management flagged ongoing spending tied to regulatory submissions for Modern Oral and warned that state tax increases are likely over time, adding pressure to category pricing. These costs represent a structural headwind but should affect the broader industry, not just Turning Point Brands.

Guidance Underscores Confidence Despite Margin Headwinds

Forward-looking guidance centers on aggressive Modern Oral growth, with 2026 net sales expected between $180 million and $190 million and gross sales up to $240 million. The company also outlined an effective tax rate of 23–26%, a core 2026 CapEx budget of $4–5 million plus $3–5 million for Modern Oral regulatory work, signaling steady reinvestment alongside disciplined capital spending.

Turning Point Brands’ earnings call painted a picture of a company in active transition, trading some near-term margin stability for outsized growth in Modern Oral and future efficiency gains from U.S. manufacturing. For investors, the key takeaway is that strong cash generation and solid core brands are funding an aggressive push into a rapidly expanding category that could reshape the company’s earnings profile over the next few years.